Safety and efficacy of ozanimod vs. fingolimod

Zeposia is an oral sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing MS.
Post Reply
User avatar
NHE
Volunteer Moderator
Posts: 5515
Joined: Sat Nov 20, 2004 3:00 pm
Contact:

Safety and efficacy of ozanimod vs. fingolimod

Post by NHE » Sat Apr 25, 2020 2:33 am

Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis.
J Comp Eff Res. 2020 Mar;9(4):275-285.
  • Aim: Ozanimod and fingolimod are sphingosine 1-phosphate receptor-modulating therapies for relapsing multiple sclerosis.

    Patients & methods: Comparative effectiveness was assessed by matching adjusted indirect comparisons of safety and efficacy trial outcomes at first-dose cardiac monitoring, 1 year and 2 years.

    Results: After adjustment, baseline characteristics were similar. Ozanimod was associated with a lower risk of extended first-dose monitoring, conduction abnormalities including atrioventricular block. One-year risks of any adverse event (AE), mean lymphocyte count reductions and abnormal liver enzymes were lower with ozanimod. Two-year risks of AEs leading to discontinuation, any AEs, herpetic infections, bradycardia and abnormal liver enzymes were lower with ozanimod. Analyses of efficacy outcomes were similar.

    Conclusion: Ozanimod appears to have a favorable benefit-risk profile versus fingolimod.

Free full text.

Post Reply
  • Similar Topics
    Replies
    Views
    Last post

Return to “Zeposia (Ozanimod)”